At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable ...
Nikolai Strusberg, MD, discussed other toxicities of proton vs photon breast RT, practice implications, and next steps in ...
With both CAR T-cell therapy and bispecific antibodies now available in early relapse, Adam D. Cohen, MD, director of Myeloma ...
Experts highlight KEYNOTE-C93, TroFuse-005, and antibody-drug conjugate data in platinum-resistant ovarian cancer at the ESMO Congress 2026.
Indocyanine green may be highly sensitive in the identification of ovarian cancer metastases, though with low specificity. One method used for intraoperative tissue imaging is indocyanine green (ICG).
Leah Katz, MD, MPH, discusses IDEA, TARGIT-B, NeoORB, and other breast radiation data from ASTRO 2026, and why patient ...
Investigators will share detailed findings from the phase 1a/b EMBOLD PanTumour-101 study at the European Society for Medical ...
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal ...
The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk ...
Matthew J. Frigault, MD, and Adam D. Cohen, MD, outline how updated NCCN guidelines position CAR T-cell therapy in early ...
Long-term QUILT-3.032 data showed a 71% CR rate, with a median duration of 26.6 months with nogapendekin alfa inbakicept/BCG in BCG-unresponsive NMIBC. The FDA assigned a PDUFA date of June 14, 2027, ...
Vitamin C is a powerful epigenetic drug, which is not generally realized,” said Peter A. Jones, PhD, DSc (hon). Patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results